Amedisys sinks into potential extension of UnitedHealth deal review

Shares of Amedisys (AMED) are moving lower into a potential regulatory update on the company’s pending takeover by UnitedHealth (UNH). Amedisys previously disclosed that on March 14, the Oregon Health Authority stated it was commencing a comprehensive review of the proposed acquisition. The notice stated that the review will be completed within 180 days of receipt of the notice of material change transaction form, which the OHA confirmed on December 4, 2023, and is subject to tolling or extension. UnitedHealth’s obligations to effect the proposed acquisition of Amedisys are subject to, among other things, approval from the Oregon Health Authority. Shares of are down 6% to $90.50 in midday trading. Amedisys and UnitedHealth’s Optum agreed to combine in an agreement that calls for the acquisition of Amedisys’s outstanding common stock in an all-cash transaction for $101 per share.